Thrombin products: economic impact of immune-mediated coagulopathies and practical formulary considerations.
Thrombin has demonstrated utility in aiding surgical hemostasis since its introduction more than 60 years ago. It is used across a wide variety of surgical procedures by virtually every specialty. Only recently have new equally effective and safe products entered the market, causing decision makers to evaluate formulary selection among products with otherwise modest differences. This evaluation includes identifying costs beyond those of acquisition and storage, as well as indirect factors such as monitoring or specialized distribution requirements. One factor to consider specifically in selection of topical thrombin products is the potential for patients to develop an immune-mediated coagulopathy (IMC) after exposure to bovine-derived thrombin. Costs due to adverse drug events fall into the category of indirect costs and, in some instances, can be substantial if bleeding due to IMC occurs.
Voils
Stacy A
SA
School of Pharmacy, Virginia Commonwealth University, and the Department of Pharmacy Services, Virginia Commonwealth University Health System, Medical College of Virginia Hospitals, Richmond, Virginia, USA. svoils@mcvh-vcu.edu
D000287:Administration, Topical; D000818:Animals; D001778:Blood Coagulation Disorders / Q000139:chemically induced / Q000191:economics* / Q000276:immunology; D002417:Cattle; D016527:Drug Costs; D005572:Formularies, Hospital as Topic; D006488:Hemostasis, Surgical / Q000191:economics / Q000379:methods; D006490:Hemostatics / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use; D006801:Humans; D019106:Postoperative Hemorrhage / Q000517:prevention & control; D013917:Thrombin / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use
D006490:Hemostatics; D013917:Thrombin